Q-omics provides the consensus-scored MIR4666A profile across patient tissues and cancer cell-line models. MIR4666A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MIR4666A is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, MIR4666A RNA expression shows 14,010 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight READ, HNSC, and TGCT as cancer lineages where MIR4666A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4666A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4666A survival associations across molecular data types. MIR4666A RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4666A RNA expression–survival associations across cancer types. High MIR4666A expression shows unfavorable associations in READ, KIRP, DLBC and CHOL, but favorable associations in LUAD and LGG. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MIR4666A RNA expression.
This table summarizes MIR4666A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4666A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4666A shows higher tumor expression in HNSC, BRCA, LIHC, THCA, PRAD and LUSC. The HNSC box plot shows higher MIR4666A RNA expression in tumor versus normal tissue (log2 FC = +0.401, t-test p < 0.001).
This table shows molecular features associated with MIR4666A in patient tissues and cancer cell lines. In patient samples, MIR4666A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
